Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
July 24, 2018 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure -- Vast majority of psoriasis patients...